ITIL-306 for Non-small Cell Lung Cancer

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Non-small Cell Lung Cancer+2 MoreITIL-306 - Biological
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing a new cell therapy for adults with solid tumors that have progressed after standard therapy. The therapy is derived from the patient's own tumor-infiltrating immune cells and is designed to increase activity against the tumor when it encounters a specific molecule on the tumor.

Eligible Conditions
  • Non-small Cell Lung Cancer
  • Ovarian Cancer
  • Kidney Cancer

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 4 Secondary · Reporting Duration: Up to 60 months

Up to 24 months
Therapeutic procedure
Up to 60 months
Duration of response (DOR)
Objective response rate (ORR)
Overall Survival (OS)
Progression-free survival (PFS)

Trial Safety

Safety Progress

1 of 3

Trial Design

2 Treatment Groups

Phase 1b: Expansion
1 of 2
Phase 1a: Dose Escalation
1 of 2

Experimental Treatment

51 Total Participants · 2 Treatment Groups

Primary Treatment: ITIL-306 · No Placebo Group · Phase 1

Phase 1b: Expansion
Biological
Experimental Group · 1 Intervention: ITIL-306 · Intervention Types: Biological
Phase 1a: Dose Escalation
Biological
Experimental Group · 1 Intervention: ITIL-306 · Intervention Types: Biological

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: up to 60 months

Who is running the clinical trial?

Instil BioLead Sponsor
2 Previous Clinical Trials
130 Total Patients Enrolled
1 Trials studying Non-small Cell Lung Cancer
Instil Study DirectorStudy DirectorInstil Bio, Inc.
2 Previous Clinical Trials
130 Total Patients Enrolled
1 Trials studying Non-small Cell Lung Cancer

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
Cohort 2: Squamous-cell carcinoma or adenocarcinoma of the lung.
You have histologically documented advanced (metastatic and/or unresectable) disease as appropriate per cohort.
You have had a complete tumor resection for TIL harvest
You have clear cell or papillary RCC.

Who else is applying?

What state do they live in?
Texas100.0%
What site did they apply to?
Washington University School of Medicine100.0%
What portion of applicants met pre-screening criteria?
Met criteria100.0%